OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.
The company believes that better and earlier detection of cancer through liquid biopsies will:
Current diagnostic standards fall short by many measures. At present, diagnostic tests for cancer rely on scans and then tissue samples from invasive surgical procedures to determine if a tumor is benign or malignant.
These invasive tests are expensive, time-consuming when time may be of utmost importance, and lead to both patient anxiety and physician uncertainty about the diagnosis.
Our next generation liquid biopsy diagnostics will use blood or urine samples to detect the presence or absence of cancer. These diagnostics are:
OncoCyte’s initial focus is on cancers with large patient populations and significant unmet need.
Net income (Q3, 2017)
EBIT (Q3, 2017)
Market capitalization (18-Apr-2018)
General and administrative expense
Operating expense total
Depreciation and Amortization
Cash From Operating Activities
|USD||Q1, 2016||Q2, 2016||Q3, 2016||Q1, 2017|
|(2.9 m)||(2.5 m)||(2.6 m)||(4.7 m)|
|403 k||192 k||870 k||211 k|
Patents and Patent Applications